2minutemedicine.com21h
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
pharmaphorum4y
GSK steals march on AZ as FDA approves Trelegy in asthma
Trelegy (fluticasone furoate+umeclidinium+vilanterol), which has been developed with partner Innoviva, is a three-in-one inhaler that is a successor to GSK’s two-in-one inhaler Advair.
Monthly Prescribing Reference3y
Trelegy Ellipta
Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...
Hosted on MSN8d
Environmentally Friendlier COPD Inhaler May Also Be More Effective
Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...
pharmaphorum5d
COPD triple approved, can GSK maximise its revenues?
Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could help patients manage their condition better - around a quarter ...